The mission of the Imaging Program is to build the capability in Ontario to accelerate translation of research findings and developments of new imaging techniques and probes of cancer into clinical practice through the critical stages.
We have 4 centres of excellence to provide the necessary expertise to the cancer research and clinical communities.
Probe Development focuses on the discovery, development, distribution, and commercialization of molecular imaging probes and targeted radiotherapeutics. This work is carried out at the Centre for Probe Development and Commercialization (CPDC) locations in Hamilton, Toronto and Ottawa.
Expertise and capabilities: The Probe Development team has the expertise to overcome the gap between probe research and clinical use. The CPDC provides the cancer research community with the collaborative support they need to access existing and novel probes. Lay expertise includes radiopharmaceutical research and development, process development and manufacturing, quality assurance, regulatory affairs and business development.
Principal Investigator: Dr. John Valliant, Founder, CPDC; Professor, Department of Chemistry and Chemical Biology, McMaster University
Contact: Dr. Joe McCann, CEO, CPDC; firstname.lastname@example.org
Medical Imaging Instrumentation and Software
Medical Imaging Instrumentation and Software (MIIS) develops image-guided interventional imaging systems that are used in a wide range of applications, from multi-modality biopsy systems to image-guided robotic techniques used for minimally invasive focal tumour ablation. This work is carried out at the Centre for Imaging Technology Commercialization (CIMTEC) and the Robarts Research Institute.
Expertise and capabilities: The MIIS team has core expertise in imaging physics and mechanical, electrical and computer engineering, needed to develop image-processing, guidance, visualization tools and robotic devices that can be used in a wide range of cancer biopsy and therapy applications. We are have core technology for robotic devices, image guidance and processing tools that can be applied to emerging clinical needs.
Capabilities include 3D multi-modality image viewing, delineation of organ and tumour margins (segmentation), fusion of multi-modality images (registration), texture analysis of images (radiomics), 3D ultrasound (3D US) biopsy guidance instrumentation, robotic systems for image-guided therapy, and image-guidance software. Access to imaging equipment includes MR scanners, ultrasound machines and CT scanners as well as fully equipped machine and electronics shops.
Principal Investigator: Dr. Aaron Fenster, CEO, CIMTEC; Chair, Division of Imaging Sciences, Department of Medical Imaging, Western University; Scientist, Robarts Research Institute; Professor, Departments of Biomedical Engineering, Oncology, Medical Imaging and Medical Biophysics, Western University;
Contact: Carol Richardson at email@example.com
Imaging Validation Core
The Imaging Validation Core (IVC) is focused on the development and validation of reliable quantitative prognostic and predictive biomarkers and validation of new imaging modalities against ground truth provided by histopathology and molecular profiling. This work is carried out at the Biomarker Imaging Research Lab at the Sunnybrook Research Institute.
Expertise and capabilities: In addition to the biomarker multiplexing capability, the lab offers full range of digital whole-mount histopathology techniques, whole mount immunohistochemistry and development of image analysis tools and digital pathology applications and biomarker multiplexing. The lab offers access to imaging-pathology validation services and resources for clinical trials and pilot projects.
Principal Investigator: Dr. Martin Yaffe, Senior Scientist, Physical Sciences, Tory Family Chair in Cancer Research, Sunnybrook Research Institute; Chief Scientific Officer, CIMTEC; Professor, Departments of Medical Biophysics and Medical Imaging, University of Toronto
Contact: Yulia Yerofeyeva at firstname.lastname@example.org
Quantitative Imaging for Personalized Cancer Medicine
Quantitative Imaging for Personalized Cancer Medicine (QIPCM) provides end-to-end data management and medical imaging solutions to help clinical trials achieve improved consistency and reliability in study data. QIPCM has established the required infrastructure and support services for international multi-centre clinical trials. QIPCM is based out of University Health Network.
Expertise and capabilities: QIPCM services for clinical trials includes a centralized data repository with remote access for multi-centre clinical trials, data anonymization and transfer, scanner quality assurance, imaging protocol development and image analysis.
Principal Investigator: Dr. David Jaffray, Senior Scientist, Princess Margaret Cancer Centre ; Executive VP Technology and Innovation, University Health Network; Director, Research Institute, Techna Institute for the Advancement of Technology for Health
Contact: Julia Publicover at Julia.Publicover@rmp.uhn.on.ca
Additional opportunities to collaborate
Please visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate.
To find out more about what’s happening in Imaging, visit OICR News.